Hydralazine target: from blood vessels to the epigenome

Journal of Translational Medicine
Claudia ArceAlfonso Dueñnas-Gonzalez

Abstract

Hydralazine was one of the first orally active antihypertensive drugs developed. Currently, it is used principally to treat pregnancy-associated hypertension. Hydralazine causes two types of side effects. The first type is an extension of the pharmacologic effect of the drug and includes headache, nausea, flushing, hypotension, palpitation, tachycardia, dizziness, and salt retention. The second type of side effects is caused by immunologic reactions, of which the drug-induced lupus-like syndrome is the most common, and provides clues to underscoring hydralazine's DNA demethylating property in connection with studies demonstrating the participation of DNA methylation disorders in immune diseases. Abnormalities in DNA methylation have long been associated with cancer. Despite the fact that malignant tumors show global DNA hypomethylation, regional hypermethylation as a means to silence tumor suppressor gene expression has attracted the greatest attention. Reversibility of methylation-induced gene silencing by pharmacologic means, which in turns leads to antitumor effects in experimental and clinical scenarios, has directed efforts toward developing clinically useful demethylating agents. Among these, the most widely used comprise...Continue Reading

References

Apr 1, 1975·Acta Medica Scandinavica·A J JounelaM J Mattila
Jan 1, 1992·Pharmacology & Therapeutics·G D Johnston
Aug 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·A de BustrosS B Baylin
Jan 1, 1967·The Medical Clinics of North America·R L Herting, H L Hunter
Sep 15, 1984·Biochemical Pharmacology·M Jacobs
Aug 1, 1984·Carcinogenesis·N ShivapurkarL A Poirier
Apr 1, 1981·Clinical Pharmacology and Therapeutics·A LitwinE V Hess
Dec 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·F Antequera, A Bird
Sep 1, 1994·Arthritis and Rheumatism·B RichardsonK O'Rourke
Apr 1, 1995·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·E J Price, P J Venables
Jan 1, 1994·Human Molecular Genetics·P W Laird, R Jaenisch
Jul 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·C De SmetT Boon
Apr 16, 1998·The Journal of Emergency Medicine·D R PowersJ D Wallin
Jun 4, 1998·Current Opinion in Genetics & Development·J R Davie
Oct 22, 1998·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·M H Kuo, C D Allis
Dec 16, 1998·European Journal of Pharmacology·L BangJ Aldershvile
Aug 23, 2000·Immunology Today·B SeligerS Ferrone
Apr 3, 2001·Annals of Internal Medicine·V SantiniJ P Issa
Aug 11, 2001·Science·W ReikJ Walter
Aug 15, 2001·Journal of Mammary Gland Biology and Neoplasia·B B Asch, M H Barcellos-Hoff
Oct 6, 2001·British Journal of Pharmacology·D C Ellershaw, A M Gurney
Oct 23, 2001·International Journal of Cancer. Journal International Du Cancer·A SerranoF Garrido
Jan 10, 2002·Genes & Development·Adrian Bird
Jul 19, 2002·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Tillmann BertBabette Simon
Aug 3, 2002·Oncogene·Susan J Clark, John Melki
Aug 23, 2002·Seminars in Cancer Biology·Elena M KlenovaVictor V Lobanenkov
Sep 24, 2002·Journal of Cellular Biochemistry·Theresa M Geiman, Keith D Robertson
Nov 7, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Goffin, E Eisenhauer
Nov 28, 2002·International Journal of Cancer. Journal International Du Cancer·Mélanie PrimeauRichard L Momparler
Dec 24, 2002·Nature Genetics·Marie-France RobertA Robert MacLeod
Jan 28, 2003·Journal of Cellular Physiology·Albert J W ZendmanGoos N P Van Muijen

❮ Previous
Next ❯

Citations

Dec 17, 2008·Annals of Biomedical Engineering·Hanping WuJohn R Haaga
Jun 11, 2011·Journal of Computer-aided Molecular Design·Jakyung Yoo, José L Medina-Franco
Apr 28, 2007·The Cancer Journal·Bodo BruecknerFrank Lyko
Aug 9, 2006·Journal of Translational Medicine·Blanca Segura-PachecoAlfonso Duenas-González
May 26, 2006·Radiation Oncology·Myrna CandelariaAlfonso Dueñas-Gonzalez
Mar 9, 2010·Journal of Biological Engineering·Youngnam ChoRichard Ben Borgens
Oct 5, 2012·Expert Opinion on Therapeutic Patents·Jacques FahyPaola B Arimondo
Jan 30, 2008·Cancer Treatment Reviews·Alfonso Duenas-GonzalezLuis A Herrera
Jul 13, 2011·Laboratory Investigation; a Journal of Technical Methods and Pathology·Yu-Hsun KaoYi-Jen Chen
Apr 27, 2007·Journal of Cellular Physiology·Luca SigalottiMichele Maio
Apr 25, 2018·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Benjamin P LarkinSonia Saad
Dec 7, 2011·Drugs·Sang-Hyun SongYung-Jue Bang
Sep 22, 2016·Clinical Epigenetics·Inês GraçaCarmen Jerónimo
Apr 22, 2011·Clinical Pharmacology and Therapeutics·M KacevskaM Ingelman-Sundberg
May 6, 2020·Pharmaceutics·Filipa Moreira-SilvaCarmen Jerónimo
Jan 11, 2020·Paediatric Drugs·Rossana Baracco
May 1, 2018·Frontiers in Pharmacology·Ângela Marques-MagalhãesCarmen Jerónimo
Sep 14, 2010·Molecular Cancer Therapeutics·Dirk KuckJose L Medina-Franco
Dec 15, 2020·Frontiers in Oncology·Michel Montalvo-CasimiroLuis A Herrera
Dec 31, 2020·Pharmaceuticals·K Eurídice Juárez-MercadoJosé L Medina-Franco
Jul 25, 2021·International Journal of Molecular Sciences·Dario KringelJörn Lötsch
Aug 7, 2021·Pharmaceuticals·Mariana Brütt PachecoCarmen Jerónimo
Feb 8, 2014·Chemical Research in Toxicology·Birandra K SinhaRonald P Mason
Dec 7, 2007·The International Journal of Biochemistry & Cell Biology·Alfredo FucitoGaetano Romano
Sep 4, 2021·European Journal of Pharmacology·Jyh-Gang LeuYao-Jen Liang
Sep 7, 2021·Frontiers in Cell and Developmental Biology·Benjamin P LarkinSonia Saad

❮ Previous
Next ❯

Methods Mentioned

BETA
acetylation
histone acetylation
antisense oligonucleotide
PCR
methyltransferase assay
electrophoresis
biopsies

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Partha M Das, Rakesh Singal
Clinical Advances in Hematology & Oncology : H&O
Ehab Atallah, Guillermo Garcia-Manero
© 2021 Meta ULC. All rights reserved